Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Fenoglio, Roberta, Sciascia, Savino, Beltrame, Giulietta, Mesiano, Paola, Ferro, Michela, Quattrocchio, Giacomo, Menegatti, Elisa, Roccatello, Dario
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper: Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://ncbi.nlm.nih.gov/pubmed/29989000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25612
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados